First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. [artículo]
Por: Cortés-Funes Castro, Hernán [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Editor: Oncology, 2012Descripción: 82(4):218-27.Recursos en línea: Solicitar documento Resumen: The prognosis for patients with triple-negative breast cancer (TNBC) is poor and treatment options are limited. Bevacizumab improves the efficacy of standard first-line therapy in locally recurrent/metastatic breast cancer (LR/mBC). The benefit of bevacizumab seen in patients with TNBC appears similar to that observed in the overall population. We conducted an exploratory analysis of patients with TNBC treated in the single-arm routine oncology practice ATHENA study.Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
---|---|---|---|---|
Artículo | PC1996 (Navegar estantería) | Disponible |
Formato Vancouver:
Thomssen C, Pierga JY, Pritchard KI, Biganzoli L, Cortés-Funes H, Petráková K, et al. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology. 2012;82(4):218-27.
PMID:22508241
Contiene 32 referencias
The prognosis for patients with triple-negative breast cancer (TNBC) is poor and treatment options are limited. Bevacizumab improves the efficacy of standard first-line therapy in locally recurrent/metastatic breast cancer (LR/mBC). The benefit of bevacizumab seen in patients with TNBC appears similar to that observed in the overall population. We conducted an exploratory analysis of patients with TNBC treated in the single-arm routine oncology practice ATHENA study.
No hay comentarios para este ejemplar.